IL113167A - Sustained release pharmaceutical excipient containing a heteropolysacharide gum granulate thereof and methods for the preparation thereof - Google Patents

Sustained release pharmaceutical excipient containing a heteropolysacharide gum granulate thereof and methods for the preparation thereof

Info

Publication number: IL113167A
Authority: IL; Israel
Prior art keywords: sustained release; excipient; linking agent; heteropolysaccharide gum; gum
Prior art date: 1994-04-25

Application number

IL11316795A

Other languages

English (en)

Hebrew (he)

Other versions

IL113167A0 (en

Original Assignee

Mendell Co Inc Edward

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-25

Filing date

1995-03-28

Publication date

2001-01-28

1995-03-28 Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward

1995-06-29 Publication of IL113167A0 publication Critical patent/IL113167A0/xx

2001-01-28 Publication of IL113167A publication Critical patent/IL113167A/en

Links

238000013268 sustained release Methods 0.000 title claims abstract description 69
239000012730 sustained-release form Substances 0.000 title claims abstract description 69
238000000034 method Methods 0.000 title claims description 17
238000002360 preparation method Methods 0.000 title description 4
239000000126 substance Substances 0.000 title description 3
239000000825 pharmaceutical preparation Substances 0.000 title 1
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 78
239000000203 mixture Substances 0.000 claims abstract description 48
125000002091 cationic group Chemical group 0.000 claims abstract description 37
239000003431 cross linking reagent Substances 0.000 claims abstract description 36
239000008187 granular material Substances 0.000 claims abstract description 19
239000008024 pharmaceutical diluent Substances 0.000 claims abstract description 12
238000004132 cross linking Methods 0.000 claims abstract description 11
239000008184 oral solid dosage form Substances 0.000 claims abstract description 11
239000003701 inert diluent Substances 0.000 claims abstract description 10
229920002472 Starch Polymers 0.000 claims abstract description 9
235000019698 starch Nutrition 0.000 claims abstract description 9
239000007864 aqueous solution Substances 0.000 claims abstract description 8
239000001913 cellulose Substances 0.000 claims abstract description 8
229940124531 pharmaceutical excipient Drugs 0.000 claims abstract description 8
239000008107 starch Substances 0.000 claims abstract description 8
229920002678 cellulose Polymers 0.000 claims abstract description 7
150000002016 disaccharides Chemical class 0.000 claims abstract description 6
150000002772 monosaccharides Chemical class 0.000 claims abstract description 6
150000005846 sugar alcohols Polymers 0.000 claims abstract description 6
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 28
229920001285 xanthan gum Polymers 0.000 claims description 22
239000000230 xanthan gum Substances 0.000 claims description 21
235000010493 xanthan gum Nutrition 0.000 claims description 21
229940082509 xanthan gum Drugs 0.000 claims description 21
239000000463 material Substances 0.000 claims description 17
230000002209 hydrophobic effect Effects 0.000 claims description 12
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 11
239000012530 fluid Substances 0.000 claims description 10
238000005550 wet granulation Methods 0.000 claims description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
230000036571 hydration Effects 0.000 claims description 9
238000006703 hydration reaction Methods 0.000 claims description 9
239000008101 lactose Substances 0.000 claims description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
239000008121 dextrose Substances 0.000 claims description 8
238000005469 granulation Methods 0.000 claims description 8
230000003179 granulation Effects 0.000 claims description 8
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
229930006000 Sucrose Natural products 0.000 claims description 6
235000010980 cellulose Nutrition 0.000 claims description 6
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
239000008108 microcrystalline cellulose Substances 0.000 claims description 6
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims description 6
NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 6
PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 6
239000005720 sucrose Substances 0.000 claims description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
229920001282 polysaccharide Polymers 0.000 claims description 5
239000005017 polysaccharide Substances 0.000 claims description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
239000005715 Fructose Substances 0.000 claims description 4
229930091371 Fructose Natural products 0.000 claims description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
239000011780 sodium chloride Substances 0.000 claims description 4
239000000600 sorbitol Substances 0.000 claims description 4
235000010356 sorbitol Nutrition 0.000 claims description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
229910021538 borax Inorganic materials 0.000 claims description 3
239000001110 calcium chloride Substances 0.000 claims description 3
229910001628 calcium chloride Inorganic materials 0.000 claims description 3
235000011148 calcium chloride Nutrition 0.000 claims description 3
239000001527 calcium lactate Substances 0.000 claims description 3
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
235000011086 calcium lactate Nutrition 0.000 claims description 3
229960002401 calcium lactate Drugs 0.000 claims description 3
238000001035 drying Methods 0.000 claims description 3
229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
235000011147 magnesium chloride Nutrition 0.000 claims description 3
229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
235000019341 magnesium sulphate Nutrition 0.000 claims description 3
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
239000011698 potassium fluoride Substances 0.000 claims description 3
235000003270 potassium fluoride Nutrition 0.000 claims description 3
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
235000011151 potassium sulphates Nutrition 0.000 claims description 3
239000001632 sodium acetate Substances 0.000 claims description 3
235000017281 sodium acetate Nutrition 0.000 claims description 3
229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
239000001509 sodium citrate Substances 0.000 claims description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
235000011083 sodium citrates Nutrition 0.000 claims description 3
239000011775 sodium fluoride Substances 0.000 claims description 3
235000013024 sodium fluoride Nutrition 0.000 claims description 3
235000010339 sodium tetraborate Nutrition 0.000 claims description 3
229910000404 tripotassium phosphate Inorganic materials 0.000 claims description 3
235000019798 tripotassium phosphate Nutrition 0.000 claims description 3
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 3
239000000811 xylitol Substances 0.000 claims description 3
229960002675 xylitol Drugs 0.000 claims description 3
235000010447 xylitol Nutrition 0.000 claims description 3
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
239000001856 Ethyl cellulose Substances 0.000 claims description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
229920002494 Zein Polymers 0.000 claims description 2
229920013820 alkyl cellulose Polymers 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
230000007613 environmental effect Effects 0.000 claims description 2
235000019325 ethyl cellulose Nutrition 0.000 claims description 2
229920001249 ethyl cellulose Polymers 0.000 claims description 2
239000003349 gelling agent Substances 0.000 claims description 2
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
239000005019 zein Substances 0.000 claims description 2
229940093612 zein Drugs 0.000 claims description 2
229920001800 Shellac Polymers 0.000 claims 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
125000005397 methacrylic acid ester group Chemical group 0.000 claims 1
239000004208 shellac Substances 0.000 claims 1
229940113147 shellac Drugs 0.000 claims 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
235000013874 shellac Nutrition 0.000 claims 1
239000001993 wax Substances 0.000 claims 1
239000003814 drug Substances 0.000 description 45
239000003826 tablet Substances 0.000 description 33
239000011159 matrix material Substances 0.000 description 22
229940079593 drug Drugs 0.000 description 13
239000000499 gel Substances 0.000 description 13
239000004615 ingredient Substances 0.000 description 10
238000007907 direct compression Methods 0.000 description 9
238000009472 formulation Methods 0.000 description 9
239000002552 dosage form Substances 0.000 description 7
229960001031 glucose Drugs 0.000 description 7
229960001375 lactose Drugs 0.000 description 7
239000000047 product Substances 0.000 description 7
238000013270 controlled release Methods 0.000 description 6
239000008023 pharmaceutical filler Substances 0.000 description 6
239000003085 diluting agent Substances 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
-1 dimethylsiloxane Chemical class 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 4
229960002237 metoprolol Drugs 0.000 description 4
230000008569 process Effects 0.000 description 4
229940032147 starch Drugs 0.000 description 4
229960004793 sucrose Drugs 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000003232 mucoadhesive effect Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical group [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000005862 Whey Substances 0.000 description 2
102000007544 Whey Proteins Human genes 0.000 description 2
108010046377 Whey Proteins Proteins 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000007922 dissolution test Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003172 expectorant agent Substances 0.000 description 2
238000001879 gelation Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
239000008188 pellet Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
241001474374 Blennius Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
AEMOLEFTQBMNLQ-AQKNRBDQSA-M D-glucopyranuronate Chemical compound OC1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-M 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920000057 Mannan Polymers 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
229920003072 Plasdone™ povidone Polymers 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000589634 Xanthomonas Species 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000002959 anti-hypotensive effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940125714 antidiarrheal agent Drugs 0.000 description 1
239000003793 antidiarrheal agent Substances 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
229960003515 bendroflumethiazide Drugs 0.000 description 1
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
150000003842 bromide salts Chemical class 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229940046978 chlorpheniramine maleate Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
229960004415 codeine phosphate Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
229960004993 dimenhydrinate Drugs 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
239000003326 hypnotic agent Substances 0.000 description 1
230000000147 hypnotic effect Effects 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000008141 laxative Substances 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960002085 oxycodone Drugs 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008019 pharmaceutical lubricant Substances 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Character Spaces And Line Spaces In Printers (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Superstructure Of Vehicle (AREA)
Memory System Of A Hierarchy Structure (AREA)
Push-Button Switches (AREA)
Compositions Of Macromolecular Compounds (AREA)
Cosmetics (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL11316795A 1994-04-25 1995-03-28 Sustained release pharmaceutical excipient containing a heteropolysacharide gum granulate thereof and methods for the preparation thereof IL113167A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US23262594A	1994-04-25	1994-04-25

Publications (2)

Publication Number	Publication Date
IL113167A0 IL113167A0 (en)	1995-06-29
IL113167A true IL113167A (en)	2001-01-28

Family

ID=22873888

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11316795A IL113167A (en)	1994-04-25	1995-03-28	Sustained release pharmaceutical excipient containing a heteropolysacharide gum granulate thereof and methods for the preparation thereof

Country Status (18)

Country	Link
EP (2)	EP1145712B1 (fi)
JP (1)	JP3279318B2 (fi)
KR (1)	KR100232020B1 (fi)
CN (1)	CN1131023C (fi)
AT (2)	ATE308318T1 (fi)
AU (1)	AU705378B2 (fi)
CA (1)	CA2164513C (fi)
DE (2)	DE69524358T2 (fi)
DK (1)	DK0706377T3 (fi)
ES (2)	ES2246961T3 (fi)
FI (1)	FI119353B (fi)
HK (1)	HK1040487B (fi)
HU (1)	HU219818B (fi)
IL (1)	IL113167A (fi)
MX (1)	MX9600022A (fi)
PT (1)	PT706377E (fi)
TW (1)	TW357085B (fi)
WO (1)	WO1995028916A1 (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6890524B1 (en)	1997-04-04	2005-05-10	Monsanto Company	Hydrolyzable delivery system using cross-linked polymeric resins as vehicles
WO1998044951A2 (en) *	1997-04-04	1998-10-15	Monsanto Company	Hydrolysable delivery system using cross-linked polymeric resins as vehicles
AU6783498A (en)	1997-04-04	1998-10-30	Monsanto Company	Ph-selective delivery system using cross-linked polymeric resins as vehicles
AU2002316582B2 (en)	2001-07-06	2007-03-15	Endo Pharmaceuticals, Inc.	Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
CA2459976A1 (en) *	2001-09-26	2003-04-03	Penwest Pharmaceuticals Company	Opioid formulations having reduced potential for abuse
CA2481091A1 (en) *	2002-04-05	2003-10-23	Penwest Pharmaceuticals Co.	Sustained release metoprolol formulations
KR101999055B1 (ko) *	2018-02-28	2019-10-01	경북대학교 산학협력단	과황산 이온 서방성 구조체, 이의 제조방법 및 이를 이용한 유기 오염 물질 처리 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4303691A (en) *	1977-11-09	1981-12-01	Anderson, Clayton & Co.	Proteinaceous food product
US4309405A (en) *	1979-08-09	1982-01-05	American Home Products Corporation	Sustained release pharmaceutical compositions
US4764380A (en) *	1982-03-22	1988-08-16	Alza Corporation	Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4795642A (en) *	1986-05-01	1989-01-03	Pharmacaps, Inc.	Gelatin-encapsulated controlled-release composition
IT1198449B (it) *	1986-10-13	1988-12-21	F I D I Farmaceutici Italiani	Esteri di alcoli polivalenti di acido ialuronico
US4994276A (en) *	1988-09-19	1991-02-19	Edward Mendell Co., Inc.	Directly compressible sustained release excipient
SE8703881D0 (sv) *	1987-10-08	1987-10-08	Haessle Ab	New pharmaceutical preparation
IT1219587B (it) *	1988-05-13	1990-05-18	Fidia Farmaceutici	Polisaccaridi carbossiilici autoreticolati
US5128143A (en) *	1988-09-19	1992-07-07	Edward Mendell Co., Inc.	Sustained release excipient and tablet formulation
US5169639A (en) *	1988-09-19	1992-12-08	Edward Mendell Co., Inc.	Controlled release verapamil tablets
HU209251B (en) *	1992-03-13	1994-04-28	Synepos Ag	Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399358A (en) *	1993-11-12	1995-03-21	Edward Mendell Co., Inc.	Sustained release formulations for 24 hour release of metroprolol
US5399362A (en) *	1994-04-25	1995-03-21	Edward Mendell Co., Inc.	Once-a-day metoprolol oral dosage form

1995
- 1995-03-21 HU HU9503456A patent/HU219818B/hu not_active IP Right Cessation
- 1995-03-21 DE DE69524358T patent/DE69524358T2/de not_active Expired - Lifetime
- 1995-03-21 KR KR1019950705841A patent/KR100232020B1/ko not_active Expired - Fee Related
- 1995-03-21 AU AU21982/95A patent/AU705378B2/en not_active Ceased
- 1995-03-21 AT AT01112778T patent/ATE308318T1/de not_active IP Right Cessation
- 1995-03-21 ES ES01112778T patent/ES2246961T3/es not_active Expired - Lifetime
- 1995-03-21 CA CA002164513A patent/CA2164513C/en not_active Expired - Fee Related
- 1995-03-21 DK DK95914917T patent/DK0706377T3/da active
- 1995-03-21 JP JP52764295A patent/JP3279318B2/ja not_active Expired - Fee Related
- 1995-03-21 AT AT95914917T patent/ATE209906T1/de active
- 1995-03-21 DE DE69534575T patent/DE69534575T2/de not_active Expired - Fee Related
- 1995-03-21 EP EP01112778A patent/EP1145712B1/en not_active Expired - Lifetime
- 1995-03-21 WO PCT/US1995/003825 patent/WO1995028916A1/en active IP Right Grant
- 1995-03-21 ES ES95914917T patent/ES2164764T3/es not_active Expired - Lifetime
- 1995-03-21 EP EP95914917A patent/EP0706377B1/en not_active Expired - Lifetime
- 1995-03-21 CN CN95190339A patent/CN1131023C/zh not_active Expired - Fee Related
- 1995-03-21 PT PT95914917T patent/PT706377E/pt unknown
- 1995-03-28 IL IL11316795A patent/IL113167A/en not_active IP Right Cessation
- 1995-04-19 TW TW084103832A patent/TW357085B/zh not_active IP Right Cessation
- 1995-12-22 FI FI956209A patent/FI119353B/fi not_active IP Right Cessation
1996
- 1996-01-03 MX MX9600022A patent/MX9600022A/es not_active IP Right Cessation
2002
- 2002-01-30 HK HK02100732.1A patent/HK1040487B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2246961T3 (es)	2006-03-01
HUT73636A (en)	1996-08-28
DE69524358T2 (de)	2002-06-13
MX9600022A (es)	1998-06-30
FI956209L (fi)	1995-12-22
EP0706377B1 (en)	2001-12-05
EP0706377A4 (en)	1996-11-06
HU219818B (hu)	2001-08-28
CN1127469A (zh)	1996-07-24
DK0706377T3 (da)	2002-04-02
DE69534575T2 (de)	2006-07-13
ATE308318T1 (de)	2005-11-15
JP3279318B2 (ja)	2002-04-30
CA2164513A1 (en)	1995-11-02
HK1040487B (zh)	2006-05-12
PT706377E (pt)	2002-05-31
EP1145712A1 (en)	2001-10-17
HU9503456D0 (en)	1996-02-28
ES2164764T3 (es)	2002-03-01
KR100232020B1 (ko)	1999-12-01
FI956209A0 (fi)	1995-12-22
WO1995028916A1 (en)	1995-11-02
IL113167A0 (en)	1995-06-29
CN1131023C (zh)	2003-12-17
EP1145712B1 (en)	2005-11-02
TW357085B (en)	1999-05-01
EP0706377A1 (en)	1996-04-17
ATE209906T1 (de)	2001-12-15
JPH08512061A (ja)	1996-12-17
CA2164513C (en)	1999-09-21
AU2198295A (en)	1995-11-16
DE69534575D1 (de)	2005-12-08
FI119353B (fi)	2008-10-31
AU705378B2 (en)	1999-05-20
HK1040487A1 (en)	2002-06-14
DE69524358D1 (de)	2002-01-17
KR960703016A (ko)	1996-06-19

Publication	Publication Date	Title
US6039980A (en)	2000-03-21	Sustained release excipient
EP0804166B1 (en)	2011-05-04	Controlled release formulation (albuterol)
US5478574A (en)	1995-12-26	Agglomerated hydrophilic complexes with multi-phasic release characteristics
EP0360562B1 (en)	1993-07-28	Directly compressible sustained release excipient
AU684944B2 (en)	1998-01-08	Once-a-day metoprolol oral dosage form
CA2231195C (en)	2003-01-21	Sustained release matrix for high-dose insoluble drugs
WO1997016172A9 (en)	1997-10-02	Controlled release formulation (albuterol)
AU2403392A (en)	1993-02-23	Controlled release verapamil tablet
EP0706377B1 (en)	2001-12-05	Sustained release excipient
MXPA96000024A (en)	1999-01-15	Form of oral dosing of metoprolol one time

Legal Events

Date	Code	Title
2001-06-14	FF	Patent granted
2001-10-31	KB	Patent renewed
2005-05-17	KB	Patent renewed
2013-04-30	KB	Patent renewed
2015-11-30	EXP	Patent expired